Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Deconvoluting the effects of P-glycoprotein on intestinal CYP3A: a major challenge.

Knight B, Troutman M, Thakker DR.

Curr Opin Pharmacol. 2006 Oct;6(5):528-32. Epub 2006 Aug 8. Review.

PMID:
16899406
3.

Transport proteins and intestinal metabolism: P-glycoprotein and cytochrome P4503A.

Christians U.

Ther Drug Monit. 2004 Apr;26(2):104-6. Review.

PMID:
15228147
4.

Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4.

Cummins CL, Jacobsen W, Benet LZ.

J Pharmacol Exp Ther. 2002 Mar;300(3):1036-45.

5.

A kinetic evaluation of the absorption, efflux, and metabolism of verapamil in the autoperfused rat jejunum.

Johnson BM, Chen W, Borchardt RT, Charman WN, Porter CJ.

J Pharmacol Exp Ther. 2003 Apr;305(1):151-8.

6.

A critical analysis of the interplay between cytochrome P450 3A and P-glycoprotein: recent insights from knockout and transgenic mice.

van Waterschoot RA, Schinkel AH.

Pharmacol Rev. 2011 Jun;63(2):390-410. doi: 10.1124/pr.110.002584. Epub 2011 Apr 13. Review.

7.
8.

Intestinal first-pass metabolism by cytochrome p450 and not p-glycoprotein is the major barrier to amprenavir absorption.

Dufek MB, Bridges AS, Thakker DR.

Drug Metab Dispos. 2013 Sep;41(9):1695-702. doi: 10.1124/dmd.113.052191. Epub 2013 Jul 2.

9.

Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data.

Benet LZ, Cummins CL, Wu CY.

Curr Drug Metab. 2003 Oct;4(5):393-8. Review.

PMID:
14529371
10.

Effect of oral ketoconazole on intestinal first-pass effect of midazolam and fexofenadine in cynomolgus monkeys.

Ogasawara A, Kume T, Kazama E.

Drug Metab Dispos. 2007 Mar;35(3):410-8. Epub 2006 Dec 1.

11.

MDR- and CYP3A4-mediated drug-drug interactions.

Pal D, Mitra AK.

J Neuroimmune Pharmacol. 2006 Sep;1(3):323-39. Epub 2006 Aug 2. Review.

PMID:
18040809
12.

Functional interactions between P-glycoprotein and CYP3A in drug metabolism.

Christians U, Schmitz V, Haschke M.

Expert Opin Drug Metab Toxicol. 2005 Dec;1(4):641-54. Review.

PMID:
16863430
13.

Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery.

Benet LZ, Izumi T, Zhang Y, Silverman JA, Wacher VJ.

J Control Release. 1999 Nov 1;62(1-2):25-31.

PMID:
10518631
14.
15.

Functional interaction of intestinal CYP3A4 and P-glycoprotein.

Kivistö KT, Niemi M, Fromm MF.

Fundam Clin Pharmacol. 2004 Dec;18(6):621-6. Review.

PMID:
15548232
16.

New insights into drug absorption: studies with sirolimus.

Paine MF, Leung LY, Watkins PB.

Ther Drug Monit. 2004 Oct;26(5):463-7. Review.

PMID:
15385826
17.

Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine.

Suzuki H, Sugiyama Y.

Eur J Pharm Sci. 2000 Nov;12(1):3-12. Review.

PMID:
11121729
18.

Unmasking the dynamic interplay between efflux transporters and metabolic enzymes.

Benet LZ, Cummins CL, Wu CY.

Int J Pharm. 2004 Jun 11;277(1-2):3-9. Review.

PMID:
15158963
19.
20.

Inhibitory effect of docosahexaenoic acid (DHA) on the intestinal metabolism of midazolam: in vitro and in vivo studies in rats.

Hirunpanich V, Murakoso K, Sato H.

Int J Pharm. 2008 Mar 3;351(1-2):133-43. Epub 2007 Oct 5.

PMID:
18082981
Items per page

Supplemental Content

Write to the Help Desk